INTRODUCTION Malaria remains a devastating disease, affecting 216 million people annually,
with 445,000 deaths occurring primarily in children under 5 years old. Malaria treatment …

Development of antimalarial compounds into clinical candidates remains costly and arduous
without detailed knowledge of the target. As resistance increases and treatment options at …

Aminoacyl transfer RNA (tRNA) synthetases (aaRSs) are attractive drug targets, and we
present class I and II aaRSs as previously unrecognized targets for adenosine 5′-…

We identify the Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS) as a
druggable target, using genetic and chemical validation. In vitro evolution of resistance with two …

Although many new anti-infectives have been discovered and developed solely using
phenotypic cellular screening and assay optimization, most researchers recognize that structure-…

Compounds acting on multiple targets are critical to combating antimalarial drug resistance.
Here, we report that the human “mammalian target of rapamycin” (mTOR) inhibitor …

Therapeutics with novel modes of action and a low risk of generating resistance are urgently
needed to combat drug-resistant Plasmodium falciparum malaria. Here, we report that the …

The Plasmodium proteasome represents a potential antimalarial drug target for compounds
with activity against multiple life cycle stages. We screened a library of human proteasome …

Antimalarial drug discovery has until recently been driven by high‐throughput phenotypic
cellular screening, allowing millions of compounds to be assayed and delivering clinical drug …

Primary Amoebic Meningoencephalitis (PAM) is caused by Naegleria fowleri, a free-living
amoeba that occasionally infects humans. While considered “rare” (but likely underreported) …